Recently, Wang et al. reported that high EGFR copy number predicts benefits from tyrosine kinase inhibitor treatment for non-small cell lung cancer patients with wild-type EGFR [22]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.